Cetrorelix acetate

SIGMA/C5249 - ≥98% (HPLC)

Synonym: Cetrotide; N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide acetic acid salt; NS-75A; SB-75

CAS Number: 145672-81-7
Empirical Formula (Hill Notation): C₇₀H₉₂ClN₁₇O₁₄ · xC₂H₄O₂
Molecular Weight: 1431.04 (free base basis)
MDL Number: MFCD08459466
Linear Formula: C₇₀H₉₂ClN₁₇O₁₄ · xC₂H₄O₂
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-C5249-5MG	5 mg	$143.00 1/EA	Add To Favorites
45-C5249-25MG	25 mg	$568.00 1/EA	Add To Favorites

This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts C5249-25MG

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
form	solid
InChI	1S/C70H92ClN17O14.C2H4O2/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44;1-2(3)4/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102);1H3,(H,3,4)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+;/m1./s1
InChI key	KFEFLCOCAHJBEA-ANRVCLKPSA-N
originator	Merck & Co., Inc., Kenilworth, NJ, U.S.
Quality Level	100
SMILES string	CC(O)=O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc3ccc(Cl)cc3)NC(=O)[C@@H](Cc4ccc5ccccc5c4)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O
solubility	methanol: 10%
storage temp.	−20°C

Application:	Cetrorelix, a luteinizing hormone releasing hormone receptor (LHRHR) antagonist, was used to study its safety, mechanism of action, metabolism, and efficacy as a therapeutic agent for the treatment of blood cancers such as multiple myeloma (MM). Cetrorelix is used to evaluate its effects on a wide range of physiological processes and malignancies that involve luteinizing hormone releasing hormone receptor signaling pathways involving processes such as steroidogenesis.
Biochem/physiol Actions:	Cetrorelix acetate is a luteinizing hormone releasing hormone receptor antagonist. It causes prepubertal reduction in bone modeling, bone density and bone strength comparable to post-menopausal bone loss.
Biochem/physiol Actions:	Cetrorelix is a luteinizing hormone releasing hormone (LHRH) receptor antagonist.
Features and Benefits:	This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
Packaging:	5, 25 mg in glass bottle

Symbol	GHS08
Signal word	Danger
Hazard statements	H360F
Precautionary statements	P201 - P280 - P308 + P313
Risk Statements	60-63
Safety Statements	22
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	−20°C
UNSPSC	51111800

To Order From a Quote